NEWS BRIEF: Utah-based Merit Medical Systems Just Spent 4X Revenue, $105 Million, to Acquire Certain Assets of EndoGastric Solutions in an All-Cash Transaction

NEWS BRIEF:  Utah-based Merit Medical Systems Just Spent 4X Revenue, $105 Million, to Acquire Certain Assets of EndoGastric Solutions in an All-Cash Transaction
Photo by JAFAR AHMED and downloaded from Unsplash on 07 July 2024.

South Jordan, Utah-based Merit Medical Systems (NASDAQ:MMSI) has acquired certain medical device assets of Redmond, Washington-based EndoGastric Solutions for $105 million in an all-cash transaction, at 4X 2023 revenue.

According to the news release announcing the asset purchase agreement, Merit has acquired the EsophyX Z+ device from EndoGastric, a platform that delivers "... a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD."

[NOTE: According to the EndoGastric website:

["Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease that affects nearly 20 percent of the U.S. population. It is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining."]
Photo of an EsophyX Z+ model device, with close-up of tissue mold showing dual fastener deployment. Image downloaded from the EndoGastric website 07 July 2024.

Given the fact that the EsophyX Z+ device generated ~$26 million of revenue for during the twelve-month period ended 31 December 2023, Merit is paying EndoGastric just over 4X against the EsophyX Z+ 2023 topline sales to acquire the GERD-focused technologies.

According to Fred Lampropoulos, Merit’s Chairman, Chief Executive Officer and Founder, the acquisition "... enhances our product portfolio in existing clinical specialties while expanding our global footprint in the multi-billion-dollar gastrointestinal market. We look forward to helping more patients by providing clinicians with a sustained and minimally invasive treatment option for chronic GERD.”  

Additionally, the company " ... expects the EsophyX Z+ acquisition (will) be accretive to (Merit's) non-GAAP gross and operating margins, non-GAAP net income, and non-GAAP (earnings per share) in the first full year post-closing."


In case you're not aware of Utah Money Watch, our goal is to publish Utah-focused monetary, financial, and/or business news, context, and analysis on a timely/regular basis, ideally information NOT available through any other source.

[You might think of us at the opposite of Bloomberg, CNBC, and/or The Wall Street Journal, each of which focus on international/national news first and rarely report on local happenings. Conversely, we are passionately focused on uncovering the most important monetary, financial, and/or business news and information that impact the organizations and people of Utah.]

Here again, the intent is to publish news, information, context, and analysis NOT available through any other source.

To that end, this article was originally published and distributed to our Subscribers at approximately 6:30am (MT) on Monday, 08 July 2024.

However, if you are seeing this report sometime after this date/time and you are interested in seeing similar reports and/or other Utah-focused monetary/financial/business news, context, and analysis write-ups in the future on an instantaneous basis when they are published, you can do so by subscribing, FOR FREE, to Utah Money Watch.

This will take less than 30 seconds and can be done from any page on the Utah Money Watch website.


1. Click on a "Subscribe" button on any Utah Money Watch webpage,
2. Enter in your name in the proper field in the popup window that appears on-screen, and
3. Enter your preferred email address in the proper field too.

That's it. And "Yes," it really is that simple.

And ... it IS free.

So we hope to see you join us as a subscriber of Utah Money Watch.


Team Utah Money Watch